SYNTARGA
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug Conjugate technology and products for the treatment of cancer. The Company's cutting-edge chemistry capabilities and unique know-how have led to the creation of its antibody empowering Potent Payload Technology. Syntarga is leveraging its proprietary technologies and expertise to generate and commercialize, alone and with partners, a portfolio of next generation Antibody-Drug Conjugate products.
SYNTARGA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2002-01-01
Address:
Nijmegen, Gelderland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.syntarga.com
Total Employee:
1001+
Status:
Active
Contact:
+31 24 372 7700
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF DoubleClick.Net Nginx CloudFront Google Adsense AdBlock Acceptable Ads Google Adsense For Domains EuroDNS DNS
Similar Organizations
Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.
GlycoDesign
GlycoDesign is a biopharmaceutical company, engages in the discovery and development of proprietary drugs for the treatment.
multimmune GmbH
multimmune GmbH, a biopharmaceutical company, engages in the discovery and development of novel products.
Current Employees Featured
Founder
Investors List
PPM Oost NV
PPM Oost NV investment in Venture Round - Syntarga
Official Site Inspections
http://www.syntarga.com
- Host name: 185.53.177.20
- IP address: 185.53.177.20
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Syntarga"
Syntarga BV - Nimwegen, Netherlands - bionity.com
Syntarga B.V. is a biopharmaceutical company creating innovative chemistries to link anticancer activity to specificity. The Company develops highly potent cell-killing drugs, releasable linker …See details»
Syntarga 2025 Company Profile: Valuation, Investors ... - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for Syntarga. Use the PitchBook Platform to explore the full profile.See details»
Syntarga - 2025 Company Profile & Team - Tracxn
Syntarga is an acqui-hired company based in Nijmegen (Netherlands), founded in 2002 by Vincent de Groot. It operates as a Develops drugs and linker technologies for Cancer and …See details»
Syntarga - Products, Competitors, Financials, Employees, …
Compare Syntarga to Competitors Biosceptre International Biosceptre International is a biopharmaceutical company engaged in developing cancer therapies within the biotechnology …See details»
Syntarga Company Profile | Management and Employees List
Syntarga Profile and History Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug Conjugate technology and …See details»
Syntarga - Headquarter Location, Corporate Office Address and …
Find business data of Syntarga. Know the headquarter data such: location, corporate office address and opening hours of Syntarga.See details»
Syntarga - VentureRadar
"Syntarga B.V. is a biopharmaceutical company creating innovative chemistries to link anticancer activity to specificity. The Company develops highly potent cell-killing drugs, releasable linker …See details»
Syntarga BV - Company Profile and News - Bloomberg Markets
Company profile page for Syntarga BV including stock price, company news, executives, board members, and contact informationSee details»
BioPharmaLink profile of Syntarga B.V., Netherlands, Nijmegen
Syntarga B.V.: Syntarga is active in site-specific (targeted) drug delivery. We offer releasable linker technologies for efficient drug targeting. Linker length and drug loading ratios can be …See details»
Syntarga BV | TREA
CC-1065 analogs and their conjugates Patent number 9,815,784 Issue date Nov 14, 2017 Syntarga B.V. Patrick Henry Beusker A61 - MEDICAL OR VETERINARY SCIENCE HYGIENESee details»
Syntarga BV - Drug pipelines, Patents, Clinical trials - Synapse
Explore Syntarga BV with its drug pipeline, therapeutic area, technology platform, 6 literature.See details»
Syntarga - Funding, Financials, Valuation & Investors
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug ConjugateSee details»
Synthon acquires Syntarga and its Antibody-Drug Conjugate …
Jun 28, 2011 Synthon announced its acquisition of Syntarga BV. Syntarga’s activities are focused on the development of innovative chemistries that arm antibodies with a cytotoxic …See details»
Syntarga - Profiles & Contacts - Crunchbase
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug ConjugateSee details»
ADCs directed against HER2 (Syntarga) - Drug Targets, Indications ...
ADCs directed against HER2 (Syntarga): a HER2 antagonists Drug, Initially developed by Syntarga BV, Now, its global highest R&D status is Pending, Mechanism: HER2 antagonists …See details»
Syntarga B.V. Overview | SignalHire Company Profile
Syntarga B.V. is a biopharmaceutical company creating innovative chemistries to link anticancer activity to specificity. The Company develops highly potent cell-killing drugs, releasable linker …See details»
Negative News Screening (Adverse Media Screening) for Syntarga …
Never miss a headline about Syntarga B.V. Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story. Used by 100+ compliance …See details»
Syntarga Announces Two Antibody-Drug Conjugate …
Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announces today that it entered into research collaborations with two undisclosed top-15 pharma companies. These …See details»
Syntarga - Growth Outlook - Crunchbase
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug ConjugateSee details»
Conexus - Conexus, Cornerstone, Synergy Merger: Name and CEO …
4 days ago Her leadership reflects the values we all share, and I’m committed to supporting her and the organization as we move forward together into this exciting new chapter.” - Trevor …See details»